Menu
Enrolling by invitation NCT03654066

Botox or Botox With Esophageal Dilation in Patients With Achalasia

Phase IV Interventional Achalasia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Botulinum toxin type A, Endoscope balloon dilator, Patient reported outcomes, Barium esophagram.
Who it may be relevant to
Registry conditions: Achalasia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Prospective Single-Blinded Randomized Controlled Trial Comparing Botox or Botox With Esophageal Dilation in Patients With Achalasia

Overview

Achalasia is a rare esophageal motility disorder. Treatment of achalasia is aimed toward palliation of symptoms. These include botox injections to the lower esophageal sphincter (LES), pneumatic dilation, surgical myotomy, and per-oral endoscopic myotomy (POEM). Botox injections are frequently used for patients that have significant comorbidities. The primary aim of this study is to assess symptomatic response of patient with achalasia to esophageal dilation and botox injection to the LES compared to standard therapy of only botox injection.

Interventions

  • Drug Botulinum toxin type A
    Botox injection in the LES
  • Device Endoscope balloon dilator
    Distal esophageal dilation
  • Other Patient reported outcomes
    Subjects will complete two patient reported outcome measures (Eckardt and MADS).
  • Diagnostic test Barium esophagram
    Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium

Primary outcome measures

  • dysphagia score [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Adults with known diagnosis of achalasia who are NOT candidates for definitive therapy with pneumatic dilation, surgical myotomy, or POEM
  • Patient undergoing routine care upper endoscopy for achalasia

Exclusion criteria

  • Less than 18 years old
  • Previous surgery for reflux or peptic ulcer disease
  • Significant medical conditions possibly placing subjects at risk to undergo endoscopy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Vanderbilt University Medical Center Endoscopy Laboratory — Nashville

Identifiers

NCT: NCT03654066 · 181420

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗